News

May 2007

Datascope Corp. Acquires Artema Medical AB

Montvale, N.J., May 24, 2007: Datascope Corp. (NASDAQ: DSCP) today announced, in continuation of its expansion of product offerings targeted toward the surgical marketplace, an agreement to acquire Artema Medical AB. Artema is a privately held Swedish manufacturer of proprietary gas analyzers, which identify and measure the concentration of anesthetic agents used during surgery. Artema is the developer of the world's most compact and power efficient side-stream gas analyzer, the Artema AION™, which is sold on an OEM-basis to patient monitoring companies. In the calendar year 2006, Artema's revenues were approximately $10 million, 35% higher than the year before.

Gas analyzers significantly enhance patient safety in surgery, and are consequently a required component of most patient monitors purchased for operating room use. The Artema AION™ provides a technologically advanced companion to Datascope's recently launched Spectrum® OR patient monitor. Datascope expects to strengthen its competitive position while reducing cost by integrating Artema's product into the Datascope Patient Monitoring line. Artema will continue to provide high-quality products and support to their OEM customers that have allowed the company to grow rapidly over the last several years. As a part of Datascope Patient Monitoring, the Artema business unit will continue to focus on adding new OEM customers.

Artema will operate as a separate business unit based in Stockholm and will continue its R&D efforts to produce the next generation of patient-related gas measurements. The Company expects that the combination of Artema's optical measurement expertise with the monitoring depth of the Datascope team will facilitate innovation in patient measurement technologies.

Over the past 18 months Datascope has introduced several products for the surgical procedure market. These products include the Spectrum OR, Anestar® Plus and the Gas Module SE™ with spirometry.

About Datascope Corp.

Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company has four product lines aggregated into two reporting segments, Cardiac Assist / Monitoring Products and Interventional Products / Vascular Grafts. The Company's products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope's website, www.datascope.com.

About Artema Medical AB
Artema's products are used to identify, measure and monitor all five anesthetic agents (HAL, ISO, ENF, SEV, DES) plus CO2, N2O and O2. Artema's products, which meet the highest international standards, are designed for easy integration into patient monitors, anesthesia delivery systems and ventilators. Artema's operations are concentrated to key competences within gas analysis. Artema prioritizes growth through focused investments in new technological development and increased market penetration. We will be a leading player in matching technological development with client-related needs and will measure our performance in terms of quality and cost-effectiveness.

This press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Many of these risks cannot be predicted or quantified and are at least partly outside our control, including the risks that Datascope will not strengthen its competitive position while reducing cost by integrating Artema's product into the Datascope Patient Monitoring line, that the combination of Artema's optical measurement expertise with the monitoring depth of the Datascope team will not facilitate innovation in patient measurement technologies, as well as other risks detailed in documents filed by Datascope with the Securities and Exchange Commission.